Completed PHASE4 INTERVENTIONAL NCT00174317

Celecoxib Versus Diclofenac In The Treatment Of Osteoarthritis Of The Hip

Clinical Protocol For A Multicentre, Double-Blind, Randomised, Parallel Group Study To Compare The Efficacy and Tolerability Of Celecoxib Vs. Diclofenac In The Treatment Of Subjects With Osteoarthritis Of The Hip Requiring Joint Replacement Therapy

Sponsor: Pfizer

Conditions Osteoarthritis, Hip

Interventions Celecoxib Diclofenac

Updated 7 times since 2017 Last updated: Nov 30, 2006 Started: Aug 31, 2003 Completion: Feb 28, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00174317, this PHASE4 trial focuses on Osteoarthritis, Hip and remains completed. Sponsored by Pfizer, it has been updated 7 times since 2003, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE4
Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Aug 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aberdeen, United Kingdom , Amersham, United Kingdom , Ashford, United Kingdom , Aston Clinton, United Kingdom , Barnsley, United Kingdom , Barry, United Kingdom , Bath, United Kingdom , Belfast, United Kingdom , Bradford, United Kingdom , Cardiff, United Kingdom and 30 more locations